Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2013 March;59(1) > Minerva Gastroenterologica e Dietologica 2013 March;59(1):49-58

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  CUTTING EDGE GASTROENTEROLOGY


Minerva Gastroenterologica e Dietologica 2013 March;59(1):49-58

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

An update on primary sclerosing cholangitis: from pathogenesis to treatment

Imam M. H. 1, Talwalkar J. A. 1, Lindor K. D. 2

1 Division of Gastroenterology and Hepatology Mayo Clinic, Cholestatic Liver Diseases Study Group, Rochester, MN, USA; 2 Office of Executive Vice Provost, Health Solutions, Arizona State University, Phoenix, AZ, USA


PDF  


Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology despite advances in medical research that have focused on uncovering its pathogenesis. Recent developments in the diagnosis of PSC including technological advances in magnetic resonanace cholangiography and the recognition of distinct clinical subtypes have led to more frequent early detection and appropriate therapy when indicated. Continued work in the areas of identifying genetic predisposing factors and novel molecular therapeutic targets are expected to create new opportunities for treating patients suffering from this chronic illness. In this review we highlight recent advances in PSC pathogenesis, diagnosis and management.

top of page

Publication History

Cite this article as

Corresponding author e-mail

keith.lindor@asu.edu